Question | Discussion | References | CME Credit

Case 3: Kaposi's Sarcoma

You answered:

D For patients with visceral Kaposi's sarcoma, bleomycin combined with vincristine is the treatment of choice.

This answer is incorrect. Visceral Kaposi's sarcoma typically requires systemic cytotoxic chemotherapy. Pegylated liposomal doxorubicin (Doxil, Dox-SL, Evacet, and LipoDox) and liposomal doxorubicin (Caelyx, Myocet) are now established as the preferred therapies. Studies comparing pegylated liposomal doxorubicin with bleomycin plus vincristine have shown better responses and fewer adverse effects with pegylated liposomal doxorubicin.

A In some patients, highly active antiretroviral therapy alone causes significant improvement of Kaposi's sarcoma lesions.
B Human herpes virus type 6 (HHV-6) is the causative agent of Kaposi's sarcoma.
C Although Kaposi's sarcoma can be serious, it is not an AIDS-defining illness.

[Back to Case 3 Question | Go to Correct Answer]